At the moment, Cronos's business is predominantly in Canada, though its American and Israeli segments are growing quickly. While its Canadian segment hasn't expanded much this year, its total quarterly revenue is growing at a rate of 29.1% year over year, which is a bit faster than Canopy. But this growth doesn't change the profitability problem. That said, Cronos may not need to take dramatic action to reach profitability, thanks to a powerful new ally.
In March of last year, Altria Group agreed to invest $1.8 billion in Cronos in exchange for a 45% share of the company. Altria is one of the world's largest tobacco product manufacturers, and its holdings include everything from major cigarette brands to newly famous e-cigarette and vaporizer companies like JUUL. So it's reasonable to expect that Altria will empower Cronos with its considerable strength in product development, brand-building, and supply chain management. As long as Altria continues to invest in improving its vaporizers, Cronos will benefit, and it will have a long-lasting competitive advantage as a result.
From all this i am expecting the stock to outperform canopy growth in the long term +4years . And seeing the price reaching 100$ or even more by 2030 .
Buy and Hold.